Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Association Between Proton Pump Inhibitors and the Incidence of Hematologic Toxicity of Pemetrexed: a Prospective, Multicenter, Observational and Longitudinal Study Among Patients Treated by a Pemetrexed-based Chemotherapy

NCT03537833 is registered in ClinicalTrials.gov with CHU de Reims as lead sponsor.

NCT NCT03537833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03537833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Association Between Proton Pump Inhibitors and the Incidence of Hematologic Toxicity of Pemetrexed: a Prospective, Multicenter, Observational and Longitudinal Study Among Patients Treated by a Pemetrexed-based Chemotherapy
Lead sponsor
CHU de Reims
Phase
Observational
Overall status
Completed
Start date
May 2, 2018
Completion date
February 11, 2022
Enrollment
172 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

patients with non-small cell lung cancer (nsclc) and pleural mesothelioma and treated with a pemetrexed-based chemotherapy